JP2019530728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530728A5 JP2019530728A5 JP2019520627A JP2019520627A JP2019530728A5 JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5 JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5
- Authority
- JP
- Japan
- Prior art keywords
- recipient
- transplantation
- antibody
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022020361A JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407167P | 2016-10-12 | 2016-10-12 | |
| US62/407,167 | 2016-10-12 | ||
| PCT/US2017/056268 WO2018071624A1 (en) | 2016-10-12 | 2017-10-12 | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Division JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530728A JP2019530728A (ja) | 2019-10-24 |
| JP2019530728A5 true JP2019530728A5 (https=) | 2020-11-12 |
| JP7256741B2 JP7256741B2 (ja) | 2023-04-12 |
Family
ID=60320981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520627A Active JP7256741B2 (ja) | 2016-10-12 | 2017-10-12 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190276524A1 (https=) |
| EP (1) | EP3526250A1 (https=) |
| JP (2) | JP7256741B2 (https=) |
| WO (1) | WO2018071624A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3529619B1 (en) | 2016-10-19 | 2021-06-30 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5a in a sample |
| EP3612561A1 (en) * | 2017-04-19 | 2020-02-26 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CN102159243B (zh) * | 2008-07-21 | 2015-08-19 | 免疫医疗公司 | 用于改良的治疗特征的抗体的结构变体 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20190127453A1 (en) * | 2016-06-07 | 2019-05-02 | Novartis Ag | An anti-c5 antibody dosing regimen |
-
2017
- 2017-10-12 WO PCT/US2017/056268 patent/WO2018071624A1/en not_active Ceased
- 2017-10-12 JP JP2019520627A patent/JP7256741B2/ja active Active
- 2017-10-12 US US16/340,453 patent/US20190276524A1/en not_active Abandoned
- 2017-10-12 EP EP17797792.3A patent/EP3526250A1/en not_active Ceased
-
2022
- 2022-02-14 JP JP2022020361A patent/JP2022051954A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530728A5 (https=) | ||
| US10647770B2 (en) | Therapeutic agent for autoimmune diseases comprising PD-1 agonist | |
| EP2430051B1 (en) | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases | |
| CN1344275A (zh) | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 | |
| JP2011006449A (ja) | 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療 | |
| FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| CN102271711B (zh) | 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂 | |
| Balfour et al. | Use of rituximab to decrease panel-reactive antibodies | |
| JP2014505056A5 (https=) | ||
| JP2025502095A5 (https=) | ||
| WO2014020922A1 (ja) | 移植片対宿主病などの造血幹細胞移植に伴う疾患を治療することのできる抗体およびその機能断片並びにこれらを含んでなる医薬組成物 | |
| Uchida et al. | Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience | |
| CA1328808C (fr) | Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme | |
| JP2024534926A5 (https=) | ||
| JP2021514368A (ja) | Ａｌｌｏ−ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ−ＣＳＦまたはＧＭ−ＣＳＦ受容体のリガンド | |
| WO2017183665A1 (ja) | 制御性ｔ細胞の活性化剤及びその使用 | |
| Yasuda et al. | The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure | |
| KR101694554B1 (ko) | 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 | |
| Amante et al. | Management of highly sensitized patients: capitol medical center experience | |
| AU2005211669C1 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| Singh et al. | Plasmapheresis vs Immunoadsorption vs Combined Plasmapheresis and Immunoadsorption Therapy: A Comparative Analysis of Desensitization Efficacy in ABO Incompatible Renal Transplant with High Baseline Titer | |
| Gupta et al. | Management of steroid-resistant acute rejection in renal transplantation | |
| CA2161797A1 (en) | Xenograft thymus | |
| Mehrotra et al. | Immunological Barriers in ABO-Incompatible Kidney Transplantation: How to Overcome |